Market capitalization | $11.73m |
Enterprise Value | $7.14m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 25.50 |
P/S ratio (TTM) P/S ratio | 41.89 |
P/B ratio (TTM) P/B ratio | 1.22 |
Revenue growth (TTM) Revenue growth | -54.82% |
Revenue (TTM) Revenue | $280.00k |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
3 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast:
3 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.28 0.28 |
55%
55%
|
|
Gross Profit | 0.19 0.19 |
-
|
|
EBITDA | -16 -16 |
15%
15%
|
EBIT (Operating Income) EBIT | -17 -17 |
17%
17%
|
Net Profit | -16 -16 |
27%
27%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.
Head office | United States |
CEO | Vincent Angotti |
Employees | 15 |
Founded | 2005 |
Website | talphera.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.